Login to Your Account

Other News To Note

Friday, September 14, 2012
• Elusys Therapeutics Inc., of Pine Brook, N.J., said it was awarded additional funding from the U.S. government, valued at $14.5 million, to support expanded human safety studies of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection following a biowarfare attack.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription